Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

June 19, 2017
Alice T. Shaw, MD, PhD

Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.